New chemo combo targets Hard-to-Treat liver cancer
NCT ID NCT04251715
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a two-step chemotherapy approach for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. First, patients received a standard chemo mix (mFOLFIRINOX) through the veins. Then, they got a second chemo drug (floxuridine) plus dexamethasone directly into the liver artery, along with more systemic chemo. The goal was to control the cancer while limiting side effects. However, the study was stopped early after enrolling only 5 people, so we have very little data on how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mFOLFIRINOX, floxuridine, dexamethasone, mFOLFIRI
What this could lead to
If successful, this approach could offer a new way to control liver-dominant cholangiocarcinoma that cannot be surgically removed.
What could go wrong
This trial was terminated early with only 5 participants, so results are very limited. The combination chemotherapy also carries risks of liver toxicity and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States